• English

    Google Translate Disclaimer

    The Maryland Department of Information Technology (“DoIT”) offers translations of the content through Google Translate. Because Google Translate is an external website, DoIT does not control the quality or accuracy of translated content. All DoIT content is filtered through Google Translate which may result in unexpected and unpredictable degradation of portions of text, images and the general appearance on translated pages. Google Translate may maintain unique privacy and use policies. These policies are not controlled by DoIT and are not associated with DoIT’s privacy and use policies. After selecting a translation option, users will be notified that they are leaving DoIT’s website. Users should consult the original English content on DoIT’s website if there are any questions about the translated content.

    DoIT uses Google Translate to provide language translations of its content. Google Translate is a free, automated service that relies on data and technology to provide its translations. The Google Translate feature is provided for informational purposes only. Translations cannot be guaranteed as exact or without the inclusion of incorrect or inappropriate language. Google Translate is a third-party service and site users will be leaving DoIT to utilize translated content. As such, DoIT does not guarantee and does not accept responsibility for, the accuracy, reliability, or performance of this service nor the limitations provided by this service, such as the inability to translate specific files like PDFs and graphics (e.g. .jpgs, .gifs, etc.).

    DoIT provides Google Translate as an online tool for its users, but DoIT does not directly endorse the website or imply that it is the only solution available to users. All site visitors may choose to use alternate tools for their translation needs. Any individuals or parties that use DoIT content in translated form, whether by Google Translate or by any other translation services, do so at their own risk. DoIT is not liable for any loss or damages arising out of, or issues related to, the use of or reliance on translated content. DoIT assumes no liability for any site visitor’s activities in connection with use of the Google Translate functionality or content.

    The Google Translate service is a means by which DoIT offers translations of content and is meant solely for the convenience of non-English speaking users of the website. The translated content is provided directly and dynamically by Google; DoIT has no direct control over the translated content as it appears using this tool. Therefore, in all contexts, the English content, as directly provided by DoIT is to be held authoritative.

    Maryland Register
    Issue Date:  October 27, 2017
    Volume 44• Issue 26 • Pages 1221—1222
    Title 10
    Subtitle 06 DISEASES
    10.06.07 Sexually Transmitted Infections — Expedited Partner Therapy for Chlamydia [and], Gonorrhea, and Trichomoniasis
    Authority: Health-General Article, §§2-104(b), 18-102, 18-201, 18-202, and 18-214.1, Annotated Code of Maryland
    Notice of Proposed Action
                    The Secretary of Health proposes to amend Regulations .01, .02, .05, and .06 and adopt new Regulation .04-1 under COMAR 10.06.07 Sexually Transmitted Infections — Expedited Partner Therapy for Chlamydia, Gonorrhea, and Trichomoniasis.
    Statement of Purpose
    The purpose of this action is to add trichomoniasis to the diseases covered under expedited partner therapy and to clarify that pharmacists are authorized to dispense expedited partner therapy per Ch. 822 (SB 110), Acts of 2017, Public Health — Expedited Partner Therapy — Trichomoniasis and Pharmacist Dispensing.
    Comparison to Federal Standards
    There is no corresponding federal standard to this proposed action.
    Estimate of Economic Impact
    I. Summary of Economic Impact. This proposal may have a minimal economic impact on Maryland Medicaid if individuals enrolled in Maryland Medicaid are prescribed and dispensed expedited partner therapy for trichomoniasis and Maryland Medicaid pays for those prescriptions.
    Revenue (R+/R-)
    II. Types of Economic Impact.
    Expenditure (E+/E-)

    A. On issuing agency:
    B. On other State agencies:
    C. On local governments:
    Benefit (+)
    Cost (-)

    D. On regulated industries or trade groups:
    E. On other industries or trade groups:
    F. Direct and indirect effects on public:
    III. Assumptions. (Identified by Impact Letter and Number from Section II.)
    A. Because the number of additional prescriptions for expedited partner therapy for trichomoniasis prescribed, dispensed, and paid for by Maryland Medicaid is likely be low, the impact on Maryland Medicaid is assumed to be minimal. The increase in the number of prescriptions that will be dispensed for expedited partner therapy is unknown. Therefore, the exact impact is indeterminate.
    Economic Impact on Small Businesses
    The proposed action has minimal or no economic impact on small businesses.
    Impact on Individuals with Disabilities
    The proposed action has no impact on individuals with disabilities.
    Opportunity for Public Comment
    Comments may be sent to Michele Phinney, Director, Office of Regulation and Policy Coordination, Maryland Department of Health, 201 West Preston Street, Room 512, Baltimore, MD 21201, or call 410-767-6499 (TTY 800-735-2258), or email to mdh.regs@maryland.gov, or fax to 410-767-6483. Comments will be accepted through January 22, 2018. A public hearing has not been scheduled.
    .01 Purpose and Scope.
    A. The purpose of expedited partner therapy in Maryland is to:
    (1) Provide antibiotic therapy to any partner of a patient diagnosed with chlamydia [or], gonorrhea, or trichomoniasis without a personal physical assessment of the partner, and without having a previous provider-patient relationship with the partner;
    (2) Contain and stop the further spread of chlamydia [and], gonorrhea, and trichomoniasis; and
    (3) (text unchanged)
    B. (text unchanged)
    .02 Definitions.
    A. (text unchanged)
    B. Terms Defined.
    (1) “Antibiotic therapy” means the oral antibiotic treatment regimens [currently]:
    (a) Currently recommended by the Centers for Disease Control and Prevention for the treatment of chlamydia and gonorrhea through expedited partner therapy[.]; and
    (b) For the treatment of trichomoniasis through expedited partner therapy:
    (i) In accordance with Regulation .05A of this chapter; and
    (ii) As authorized by Health-General Article, §18-214.1, Annotated Code of Maryland.
    (2) (text unchanged)
    (3) “Expedited partner therapy (EPT)” means the prescribing or dispensing of antibiotic therapy to any partner of a patient diagnosed with chlamydia [or], gonorrhea, or trichomoniasis by certain health care providers without making a personal physical assessment of the partner, and without having a previous provider-patient relationship with the partner, in order to contain and stop the further spread of the infection and reduce the likelihood of reinfection in the diagnosed patient.
    (4)—(5) (text unchanged)
    .04-1 Pharmacists Authorized to Dispense EPT.
    Notwithstanding any other provision of law, a pharmacist licensed under Health Occupations Article, Title 12, Annotated Code of Maryland, may dispense antibiotic therapy for EPT prescribed in accordance with Regulation .04 of this chapter.
    .05 Prescribing and Dispensing EPT Medications.
    A. Antibiotic therapy prescribed or dispensed for EPT shall be in accordance with treatment recommendations from the Centers for Disease Control and Prevention.
    B. Prescribing.
    (1) A separate prescription shall be issued for each partner[;].
    (2) The designation “EPT” or “Expedited Partner Therapy” shall be included on the face of the prescription for each prescription issued[;].
    (3) If the partner’s name is known, the prescription shall be issued in the partner’s name[;].
    (4) If the partner’s name is unknown, the written designation “EPT” or “expedited partner therapy” shall be sufficient for the pharmacist to fill the prescription[; and].
    (5) (text unchanged)
    C. (text unchanged)
    .06 Counseling and Educational Information Requirements.
    A.—B. (text unchanged)
    C. The educational information, that is available or comparable to that available on the Department’s website, shall include:
    (1) (text unchanged)
    (2) Information about chlamydia [and], gonorrhea, and trichomoniasis;
    (3)—(5) (text unchanged)
    Secretary of Health